BangladeshTuberculosis profile
Population  2014 159 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 81 (59–110) 51 (37–68)
Mortality (HIV+TB only) 0.18 (0.14–0.22) 0.11 (0.09–0.14)
Prevalence  (includes HIV+TB) 640 (340–1 000) 404 (211–659)
Incidence  (includes HIV+TB) 360 (320–410) 227 (200–256)
Incidence (HIV+TB only) 0.57 (0.45–0.71) 0.36 (0.28–0.45)
         
Case detection, all forms (%) 53 (47–60)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.4 (0.7–2.5) 29 (24–34)
MDR-TB cases among notified pulmonary
TB cases
2 100 (1 000–3 700) 2 700 (2 200–3 200)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 106 767   2 989
Pulmonary, clinically diagnosed 42 832   863
Extrapulmonary 37 406   309
       
Total new and relapse 191 166    
Previously treated, excluding relapses 5 631    
Total cases notified 196 797    
Among 187 005 new cases:
6 262 (3%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 12 573 (12%) 4 959 (51%) 43 360
Laboratory-confirmed RR-/MDR-TB cases     994
Patients started on MDR-TB treatment ***     945
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 110 (<1)
HIV-positive TB patients 45 (4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 45 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 45 (100)
HIV-positive people screened for TB 726  
HIV-positive people provided with IPT 0  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (93) 184 077
Previously treated cases, excluding relapse, registered in 2013 (86) 6 327
HIV-positive TB cases, all types, registered in 2013 (75) 68
RR-/MDR-TB cases started on second-line treatment in 2012 (72) 505
XDR-TB cases started on second-line treatment in 2012 (25) 4
Laboratories 2014  
Smear (per 100 000 population) 0.7
Culture (per 5 million population) <0.1
Drug susceptibility testing (per 5 million population) <0.1
Sites performing Xpert MTB/RIF 38
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 48
% Funded domestically <1%
% Funded internationally 70%
% Unfunded 30%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-25 Data: www.who.int/tb/data